Characterization of an Ex vivo femoral head model assessed by markers of bone and cartilage turnover

Cartilage

Volumn 2, Issue 3, 2011, Pages 265-278

  Madsen, Suzi Hoegh ^a   Goettrup, Anne Sofie ^a   Thomsen, Gedske ^a   Christensen, Søren Tvorup ^b   Schultz, Nikolaj ^a   Henriksen, Kim ^a   Bay Jensen, Anne Christine ^a   Karsdal, Morten Asser ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cytokines; Ex vivo; Femoral head; Growth plate; IGF I; Osteoarthritis

Indexed keywords

EID: 80053561382     PISSN: 19476035     EISSN: 19476043     Source Type: Journal    
DOI: 10.1177/1947603510383855     Document Type: Article

References (45)

1. Felson DT, Neogi T. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum. 2004;50(2):341-344.
2. Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res. 1986;213:34-40.
3. Dieppe P, Cushnaghan J, Young P, Kirwan J. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis. 1993;52(8):557-563.
4. Ratcliffe A, Seibel MJ. Biochemical markers of osteoarthritis. Curr Opin Rheumatol. 1990;2(5):770-776.
5. Rogers J, Shepstone L, Dieppe P. Is osteoarthritis a systemic disorder of bone? Arthritis Rheum. 2004;50(2):452-457.
6. Wohl GR, Shymkiw RC, Matyas JR, Kloiber R, Zernicke RF. Periarticular cancellous bone changes following anterior cruciate ligament injury. J Appl Physiol. 2001;91(1):336-342.
7. Boyd SK, Matyas JR, Wohl GR, Kantzas A, Zernicke RF. Early regional adaptation of periarticular bone mineral density after anterior cruciate ligament injury. J Appl Physiol. 2000;89(6):2359-2364.
8. Boyd SK, Muller R, Zernicke RF. Mechanical and architectural bone adaptation in early stage experimental osteoarthritis. J Bone Miner Res. 2002;17(4):687-694.
9. Burr DB, Radin EL. Microfractures and microcracks in subchondral bone: are they relevant to osteoarthrosis? Rheum Dis Clin North Am. 2003;29(4):675-685.
10. Dedrick DK, Goulet R, Huston L, Goldstein SA, Bole GG. Early bone changes in experimental osteoarthritis using microscopic computed tomography. J Rheumatol Suppl. 1991;27:44-45.
11. Dedrick DK, Goldstein SA, Brandt KD, O'Connor BL, Goulet RW, Albrecht M. A longitudinal study of subchondral plate and trabecular bone in cruciate-deficient dogs with osteoarthritis followed up for 54 months. Arthritis Rheum. 1993;36(10):1460-1467.
12. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 2004;50(4):1193-1206.
13. Westacott CI, Webb GR, Warnock MG, Sims JV, Elson CJ. Alteration of cartilage metabolism by cells from osteoarthritic bone. Arthritis Rheum. 1997;40(7):1282-1291.
14. Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY, Henrotin YE. Subchondral bone osteoblasts induce phenotypic changes in human osteoarthritic chondrocytes. Osteoarthritis Cartilage. 2005;13(11):988-997.
15. Sanchez C, Deberg MA, Piccardi N, Msika P, Reginster JY, Henrotin YE. Osteoblasts from the sclerotic subchondral bone downregulate aggrecan but upregulate metalloproteinases expression by chondrocytes: this effect is mimicked by interleukin-6, -1beta and oncostatin M pre-treated non-sclerotic osteoblasts. Osteoarthritis Cartilage. 2005;13(11):979-987.
16. Takahashi N, Udagawa N, Takami M, Suda T. Cells of bone: osteoclast generation. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. Vol. 1. 2nd ed. San Diego: Academic Press; 2002. p. 109-126.
17. Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J Bone Miner Res. 2001;16(6):1015-1027.
18. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem. 1994;40(11 Pt 1):2022-2025.
19. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 2001;29(3):209-215.
20. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol. 2005;3(5):553-580.
21. Madsen SH, Sondergaard BC, Bay-Jensen AC, Karsdal MA. Cartilage formation measured by a novel PIINP assay suggests that IGF-I does not stimulate but maintains cartilage formation ex vivo. Scand J Rheumatol. 2009;38(3):222-226.
22. Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokinestimulated articular cartilage degradation. Osteoarthritis Cartilage. 2006;14(8):738-748.
23. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum. 2004;50(8):2547-2558.
24. Hoegh-Andersen P, Tanko LB, Andersen TL, Lundberg CV, Mo JA, Heegaard AM, et al. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application.Arthritis Res Ther. 2004;6(2):R169-R180.
25. Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage. 2007;15(3):335-342.
26. Bay-Jensen AC, Andersen TL, Charni-Ben TN, Kristensen PW, Kjaersgaard-Andersen P, Sandell L, et al. Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage. Osteoarthritis Cartilage. 2008;16(5):615-623.
27. Oettmeier R, Abendroth K. Osteoarthritis and bone: osteologic types of osteoarthritis of the hip. Skeletal Radiol. 1989;18(3):165-174.
28. Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, PastoureauP, Karsdal MA. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon? Pharmacol Res. 2008;58(1):1-7.
29. Keraplis AC. Embryonic development of bone and the molecular regulation of intramembranous and endochondral bone formation. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. Vol. 1. 2nd ed. San Diego: Academic Press; 2002. p. 33-58.
30. von der MK, Kirsch T, Nerlich A, Kuss A, Weseloh G, Gluckert K, et al. Type X collagen synthesis in human osteoarthritic cartilage: indication of chondrocyte hypertrophy. Arthritis Rheum. 1992;35(7):806-811.
31. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008;10(3):R63.
32. Nilsson O, Marino R, De LF, Phillip M, Baron J. Endocrine regulation of the growth plate. Horm Res. 2005;64(4):157-165.
33. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology. 2007;148(7):3122-3130.
34. Pass C, Macrae VE, Ahmed SF, Farquharson C. Inflammatory cytokines and the GH/IGF-I axis: novel actions on bone growth. Cell Biochem Funct. 2009;27(3):119-127.
35. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol. 1987;138(3):775-779.
36. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. J Exp Med. 2000;191(2):275-286.
37. Weir EC, Horowitz MC, Baron R, Centrella M, Kacinski BM, Insogna KL. Macrophage colony-stimulating factor release and receptor expression in bone cells. J Bone Miner Res. 1993;8(12):1507-1518.
38. Felix R, Fleisch H, Elford PR. Bone-resorbing cytokines enhance release of macrophage colony-stimulating activity by the osteoblastic cell MC3T3-E1. Calcif Tissue Int. 1989;44(5):356-360.
39. Sato K, Kasono K, Fujii Y, Kawakami M, Tsushima T, Shizume K. Tumor necrosis factor type alpha (cachectin) stimulates mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2. Biochem Biophys Res Commun. 1987;145(1):323-329.
40. Heymann D, Rousselle AV. gp130 cytokine family and bone cells. Cytokine. 2000;12(10):1455-1468.
41. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A. 1993;90(24):11924-11928.
42. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine. 2000; 12(6):613-621.
43. Wang Y, Nishida S, Elalieh HZ, Long RK, Halloran BP, Bikle DD. Role of IGF-I signaling in regulating osteoclastogenesis. J Bone Miner Res. 2006;21(9):1350-1358.
44. Chihara K, Sugimoto T. The action of GH/IGF-I/IGFBP in osteoblasts and osteoclasts. Horm Res. 1997;48(Suppl 5): 45-49.
45. Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum. 2007;56(5):1549-1558.